Anti-CD20 x Anti-CD22 Bispecific Antibody (IgG-IgG) (BSIG-049)

Anti-CD20 x Anti-CD22 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD20 and anti-CD22 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb is designed for the research of Lymphoma; Leukemia; Antoimmune disease; Immune dysfunction disease therapy.

Datasheet

Specifications

Targets

CD20 & CD22

Type

IgG-IgG

Species Reactivity

Human

Target 1

CD20

Host Animal 1

Mouse

Target 2

CD22

Host Animal 2

Mouse

Application

FuncS; Promising therapeutic agent

Related Disease

Lymphoma; Leukemia; Antoimmune disease; Immune dysfunction disease

Targets

Target 1

CD20

Gene ID

931

UniProt ID

A0A024R507

Alternative Names

MS4A1; membrane-spanning 4-domains, subfamily A, member 1; B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; B-lymphocyte antigen CD20; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1

Target 2

CD22

Gene ID

933

UniProt ID

P20273

Alternative Names

CD22; CD22 molecule; Cluster of differentiation 22; SIGLEC2; SIGLEC-2; B-cell receptor CD22; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

UK
167-169 Great Portland Street, 5th Floor, London, W1W 5PE
Tel: 44-207-097-1828
Email: